Drug Management of Prostate Cancer [recurso electrónico] / edited by William D. Figg, Cindy H. Chau, Eric J. Small.

Por: Figg, William D [editor.]Colaborador(es): Chau, Cindy H [editor.] | Small, Eric J [editor.] | SpringerLink (Online service)Tipo de material: TextoTextoEditor: New York, NY : Springer New York : Imprint: Springer, 2010Descripción: XVII, 428p. 34 illus., 22 illus. in color. online resourceTipo de contenido: text Tipo de medio: computer Tipo de portador: online resourceISBN: 9781603278294Tema(s): Medicine | Internal medicine | Oncology | Urology | Medicine & Public Health | Oncology | Urology/Andrology | Internal MedicineFormatos físicos adicionales: Printed edition:: Sin títuloClasificación CDD: 616.994 Clasificación LoC:RC254-282Recursos en línea: Libro electrónicoTexto
Contenidos:
Cell Biology of Prostate Cancer and Molecular Targets -- Cell Biology of Prostate Cancer and Molecular Targets -- Hormone Therapy -- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer -- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer -- Androgens and Prostate Cancer -- Androgen Receptor Biology in Prostate Cancer -- Androgen Receptor Antagonists -- 5-Alpha Reductase Inhibitors in Prostate Cancer -- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer -- Androgen Deprivation Therapy -- Pharmacogenetics of the Androgen Metabolic Pathway -- Chemotherapy -- Mitoxantrone -- Docetaxel -- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer -- Platinum Agents in Prostate Cancer -- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer -- Microtubule Targeting Agents -- Angiogenesis -- Principles of Antiangiogenic Therapy -- Bevacizumab in Advanced Prostate Cancer -- Thalidomide and Analogs -- Investigational Angiogenesis Inhibitors -- Pharmacogenetics of Angiogenesis -- Bone Metastasis -- Pathophysiology of Prostate Cancer Bone Metastasis -- Radiopharmaceuticals -- Bisphosphonates for Prevention and Treatment of Bone Metastases -- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer -- Calcitriol and Vitamin D Analogs -- Immunotherapy -- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches -- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer -- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX -- CTLA-4 Blockade for Prostate Cancer Treatment -- Prevention -- Prostate Cancer Chemoprevention Strategies -- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk -- Inflammation as a Target in Prostate Cancer -- Drug Development -- Challenges for the Development of New Agents in Prostate Cancer -- FDA Approval of Prostate Cancer Treatments -- Applications of Proteomics in Prostate Cancer -- Erratum to: Docetaxel -- Erratum to: Docetaxel.
En: Springer eBooksResumen: This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry
Star ratings
    Valoración media: 0.0 (0 votos)
Existencias
Tipo de ítem Biblioteca actual Colección Signatura Copia número Estado Fecha de vencimiento Código de barras
Libro Electrónico Biblioteca Electrónica
Colección de Libros Electrónicos RC254 -282 (Browse shelf(Abre debajo)) 1 No para préstamo 372549-2001

Cell Biology of Prostate Cancer and Molecular Targets -- Cell Biology of Prostate Cancer and Molecular Targets -- Hormone Therapy -- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer -- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer -- Androgens and Prostate Cancer -- Androgen Receptor Biology in Prostate Cancer -- Androgen Receptor Antagonists -- 5-Alpha Reductase Inhibitors in Prostate Cancer -- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer -- Androgen Deprivation Therapy -- Pharmacogenetics of the Androgen Metabolic Pathway -- Chemotherapy -- Mitoxantrone -- Docetaxel -- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer -- Platinum Agents in Prostate Cancer -- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer -- Microtubule Targeting Agents -- Angiogenesis -- Principles of Antiangiogenic Therapy -- Bevacizumab in Advanced Prostate Cancer -- Thalidomide and Analogs -- Investigational Angiogenesis Inhibitors -- Pharmacogenetics of Angiogenesis -- Bone Metastasis -- Pathophysiology of Prostate Cancer Bone Metastasis -- Radiopharmaceuticals -- Bisphosphonates for Prevention and Treatment of Bone Metastases -- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer -- Calcitriol and Vitamin D Analogs -- Immunotherapy -- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches -- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer -- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX -- CTLA-4 Blockade for Prostate Cancer Treatment -- Prevention -- Prostate Cancer Chemoprevention Strategies -- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk -- Inflammation as a Target in Prostate Cancer -- Drug Development -- Challenges for the Development of New Agents in Prostate Cancer -- FDA Approval of Prostate Cancer Treatments -- Applications of Proteomics in Prostate Cancer -- Erratum to: Docetaxel -- Erratum to: Docetaxel.

This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry

19

Con tecnología Koha